Page 41 - JCBP-3-3

Journal of Clinical and
Basic Psychosomatics Microbiota in psychosomatic disorders

while another may use a single-strain formulation, leading and unintended consequences of altering gut microbial
to potentially different outcomes. Without standardized communities. 119
protocols, it is difficult to establish consensus on which In addition, human studies face practical limitations,
interventions are most beneficial. 113 such as participants’ adherence to dietary or probiotic
Furthermore, clinical trials on gut–brain axis interventions, which can affect study outcomes. Long-
interventions often lack clear reporting on adverse effects, term adherence to specialized diets (e.g., Mediterranean
dropout rates, and the long-term sustainability of microbial or ketogenic diets) or probiotic supplementation can be
changes induced by treatments. This limits the ability to difficult to maintain, leading to variability in the data and
assess the safety and long-term efficacy of interventions reduced effectiveness of the interventions being tested. 120
aimed at altering gut microbiota for mental health benefits.
4.1. Potential for personalized medicine
The complexity of microbiota-host interactions poses
another significant challenge in gut microbiota research. The potential for personalized medicine in gut microbiota
The gut microbiota interacts with the host through research is a rapidly emerging area with significant
numerous biological pathways, including immune implications for the treatment of mental health disorders,
modulation, metabolic regulation, and neurotransmitter GI conditions, and other systemic diseases. Personalized
production, all of which influence brain function and medicine aims to tailor treatments based on an individual’s
mood. However, disentangling these complex interactions unique microbiota composition, genetic profile, lifestyle
is difficult, as many of these pathways are interdependent factors, and disease status, optimizing therapeutic
and influenced by multiple factors. 114,115 For example, gut outcomes by considering the complex interplay between
121
microbiota produces SCFAs, such as butyrate, which have the gut, brain, and body. While promising, the
anti-inflammatory effects and can affect brain function by application of personalized medicine in this field faces
modulating the BBB and neuroinflammation. However, challenges related to the diversity of gut microbiota, the
SCFA production is highly dependent on the availability need for advanced diagnostic tools, and the development
of dietary fiber, the composition of the gut microbiota, and of targeted interventions. However, recent advances
host metabolic responses, making it difficult to attribute in microbiome research, computational biology, and
mental health improvements solely to microbial changes. precision therapeutics highlight the growing potential
Moreover, immune system activation in response to gut of personalized approaches to improve both mental and
dysbiosis may drive neuroinflammation, but identifying physical health outcomes. 122
the exact microbial triggers of this immune response One of the key drivers behind personalized medicine
remains challenging due to the sheer complexity of the gut in gut microbiota research is the high degree of individual
ecosystem. 116,117 variability in microbial composition. Each person’s gut
Another limitation is the difficulty in establishing microbiota is influenced by a combination of genetic
causality. Most studies are observational or cross-sectional, factors, diet, environment, medication use, and lifestyle
making it challenging to determine whether gut microbiota choices, making it highly personalized. 123,124 Studies have
changes are the cause or consequence of psychiatric shown that even among healthy individuals, there is
conditions. Longitudinal studies and well-controlled significant variation in the abundance of different bacterial
118
125
interventions are necessary to clarify the directionality species and their metabolic functions. This variability
of the relationship between gut microbiota and mental means that the one-size-fits-all approach to gut microbiota-
health, but such studies are resource-intensive and require targeted therapies, such as probiotics or pre-biotics, may
long-term follow-up. not be effective for everyone.
Ethical and practical constraints also limit gut For example, a probiotic that benefits one individual
microbiota research, particularly in human studies. by promoting the growth of beneficial bacteria, such as
Randomized controlled trials, the gold standard for Bifidobacterium may have little or no effect on another
establishing causality, are often difficult to conduct in this person whose microbiota already harbors high levels of
field due to the complexity of microbiota-host interactions, that species. In some cases, the same probiotic strain may
126
the need for individualized treatments, and the potential even lead to adverse effects if the individual’s gut is already
risks associated with certain interventions, such as FMT. imbalanced. Therefore, personalized medicine in this
While FMT has shown promise in treating GI conditions, context requires a detailed understanding of an individual’s
such as C. difficile infection, its use in psychiatric baseline microbiota composition and the identification of
conditions remains experimental and raises ethical specific microbial deficiencies or imbalances that need to
questions regarding donor selection, long-term safety, be addressed.

Volume 3 Issue 3 (2025) 35 doi: 10.36922/JCBP025040008